101. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A (2002) Characterization of rpoB mutations in
rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA
sequencing and line probe assay. J Clin Microbiol 40:4435–4438
102. Lin W, Mandal S, Degen D, Liu Y, Ebright YW, Li S, Feng Y, Zhang Y, Mandal S, Jiang Y
(2017) Structural basis of Mycobacterium tuberculosis transcription and transcription
inhibition. Mol Cell 66:169–179
103. Wang Q, Xu Y, Gu Z, Liu N, Jin K, Li Y, Crabbe MJC, Zhong Y (2018) Identification of
new antibacterial targets in RNA polymerase of Mycobacterium tuberculosis by detecting
positive selection sites. Comput Biol Chem 73:25–30
104. Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J,
Beer D (2008) Lipiarmycin targets RNA polymerase and has good activity against multidrugresistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 62:713–719
105. Scharf NT, Molodtsov V, Kontos A, Murakami KS, Garcia GA (2017) Novel chemical
scaffolds for inhibition of rifamycin-resistant RNA polymerase discovered from
high-throughput screening. SLAS Discov Adv Life Sci R&D 22:287–297
106. Hong W, Deng W, Xie J (2013) The structure, function, and regulation of mycobacterium
FtsZ. Cell Biochem Biophys 65:97–105
107. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ,
Ojima I (2006) Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as
novel antituberculosis agents. J Med Chem 49:463–466
108. Das D, Borah M, Singh AK, Das R, Boruah HPD (2015) Molecular docking of
phytochemical as Ftsz cell division protein inhibitor in Mycobacterium tuberculosis. Int J
Pharm Sci Res 6:463–472
109. Brötz-Oesterhelt H, Sass P (2014) Bacterial caseinolytic proteases as novel targets for
antibacterial treatment. Int J Med Microbiol 304:23–30
110. Raju RM, Unnikrishnan M, Rubin DH, Krishnamoorthy V, Kandror O, Akopian TN,
Goldberg AL, Rubin EJ (2012) Mycobacterium tuberculosis ClpP1 and ClpP2 function
together in protein degradation and are required for viability in vitro and during infection.
PLoS Pathog 8:e1002511
111. Gavrish E, Sit CS, Cao S, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A,
Hughes D, Bissell A (2014) Lassomycin, a ribosomally synthesized cyclic peptide, kills
Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem
Biol 21:509–518
112. Schmitz KR, Carney DW, Sello JK, Sauer RT (2014) Crystal structure of Mycobacterium
tuberculosis ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding
and substrate delivery. Proc Natl Acad Sci 111:E4587–E4595
113. Darwin KH, Ehrt S, Gutierrez-Ramos J-C, Weich N, Nathan CF (2003) The proteasome
of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302:
1963–1966
114. Gandotra S, Schnappinger D, Monteleone M, Hillen W, Ehrt S (2007) In vivo gene silencing
identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist
in mice. Nat Med 13:1515–1520
115. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M (2012)
Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium
tuberculosis. J Med Chem 55:3739–3755
116. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK,
Chatterjee D, Biswas K, Narayanasamy P (2009) Menaquinone synthesis is critical for
maintaining mycobacterial viability during exponential growth and recovery from
non-replicating persistence. Mol Microbiol 72:85–97
117. Cagan R (2016) Drug screening using model systems: some basics. Dis Models Mech
9:1241–1244
118. Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, Bhakta S (2015) Repurposing-a
ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis (IJID) Off
Publ Int Soc Infect Dis 32:50–55
Impact of Target-Based Drug Design in Anti-bacterial …
343
rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA
sequencing and line probe assay. J Clin Microbiol 40:4435–4438
102. Lin W, Mandal S, Degen D, Liu Y, Ebright YW, Li S, Feng Y, Zhang Y, Mandal S, Jiang Y
(2017) Structural basis of Mycobacterium tuberculosis transcription and transcription
inhibition. Mol Cell 66:169–179
103. Wang Q, Xu Y, Gu Z, Liu N, Jin K, Li Y, Crabbe MJC, Zhong Y (2018) Identification of
new antibacterial targets in RNA polymerase of Mycobacterium tuberculosis by detecting
positive selection sites. Comput Biol Chem 73:25–30
104. Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J,
Beer D (2008) Lipiarmycin targets RNA polymerase and has good activity against multidrugresistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 62:713–719
105. Scharf NT, Molodtsov V, Kontos A, Murakami KS, Garcia GA (2017) Novel chemical
scaffolds for inhibition of rifamycin-resistant RNA polymerase discovered from
high-throughput screening. SLAS Discov Adv Life Sci R&D 22:287–297
106. Hong W, Deng W, Xie J (2013) The structure, function, and regulation of mycobacterium
FtsZ. Cell Biochem Biophys 65:97–105
107. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ,
Ojima I (2006) Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as
novel antituberculosis agents. J Med Chem 49:463–466
108. Das D, Borah M, Singh AK, Das R, Boruah HPD (2015) Molecular docking of
phytochemical as Ftsz cell division protein inhibitor in Mycobacterium tuberculosis. Int J
Pharm Sci Res 6:463–472
109. Brötz-Oesterhelt H, Sass P (2014) Bacterial caseinolytic proteases as novel targets for
antibacterial treatment. Int J Med Microbiol 304:23–30
110. Raju RM, Unnikrishnan M, Rubin DH, Krishnamoorthy V, Kandror O, Akopian TN,
Goldberg AL, Rubin EJ (2012) Mycobacterium tuberculosis ClpP1 and ClpP2 function
together in protein degradation and are required for viability in vitro and during infection.
PLoS Pathog 8:e1002511
111. Gavrish E, Sit CS, Cao S, Kandror O, Spoering A, Peoples A, Ling L, Fetterman A,
Hughes D, Bissell A (2014) Lassomycin, a ribosomally synthesized cyclic peptide, kills
Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem
Biol 21:509–518
112. Schmitz KR, Carney DW, Sello JK, Sauer RT (2014) Crystal structure of Mycobacterium
tuberculosis ClpP1P2 suggests a model for peptidase activation by AAA+ partner binding
and substrate delivery. Proc Natl Acad Sci 111:E4587–E4595
113. Darwin KH, Ehrt S, Gutierrez-Ramos J-C, Weich N, Nathan CF (2003) The proteasome
of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302:
1963–1966
114. Gandotra S, Schnappinger D, Monteleone M, Hillen W, Ehrt S (2007) In vivo gene silencing
identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist
in mice. Nat Med 13:1515–1520
115. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M (2012)
Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium
tuberculosis. J Med Chem 55:3739–3755
116. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK,
Chatterjee D, Biswas K, Narayanasamy P (2009) Menaquinone synthesis is critical for
maintaining mycobacterial viability during exponential growth and recovery from
non-replicating persistence. Mol Microbiol 72:85–97
117. Cagan R (2016) Drug screening using model systems: some basics. Dis Models Mech
9:1241–1244
118. Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, Bhakta S (2015) Repurposing-a
ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis (IJID) Off
Publ Int Soc Infect Dis 32:50–55
Impact of Target-Based Drug Design in Anti-bacterial …
343